TECH logo

BIO-TECHNE CORP

TECHNASDAQ
πŸ† #736 by market capEarnings Feb 2US Equity
β€”β€”
Quote unavailable
πŸ””
Track TECH
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$11.42B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.4%
Declining
πŸ“ŠGross Margin
66.2%
High
πŸ’΅FCF Margin
21.7%
Strong
βš–οΈP/S Ratio
9.4x
Elevated
Otter Score
64
Fair
No chart data available for TECH.

Trading Snapshot

Day Range
β€”
52-Week Range
$43.20 – $72.88
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
157.1M
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$1.22B
Last Q Revenue
$300M
P/E Ratio
62.8
P/S Ratio
9.4x
EPS (TTM)
$1.16
Dividend Yield
0.44%
Dilution (1yr)
+0.6%
TECH logo

BIO-TECHNE CORP

TECH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.2Bβ–Ό βˆ’0.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.8%β–² +1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$252Mβ–² +146.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$263Mβ–² +2.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
157.9Mβ–² +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$64Mβ–² +$242M YoY
StockOtter Β· stockotter.space

About BIO-TECHNE CORP

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Hold
19 analysts
Strong Buy0
Buy0
Hold15
Sell1
Strong Sell3
Ratings as of Nov 2026

Latest News & Updates

News unavailable.